Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency

Journal of Pediatrics

Volumn 139, Issue 1, 2001, Pages 44-50

  Rogers, Mary Haslinger ^a,b,c,d   Lwin, Rebekah ^a,b,c,d   Fairbanks, Lynette ^a,b,c,d   Gerritsen, Bert ^a,b,c,d   Gaspar, Hubert B ^a,b,c,d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Medisch Centrum Rijnmond Zuid   (Netherlands)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE;

ADOLESCENT; AGE; ARTICLE; BEHAVIOR DISORDER; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; COGNITIVE DEFECT; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME DEFICIENCY; FEMALE; HUMAN; INFANT; INTELLIGENCE QUOTIENT; MALE; METABOLIC DISORDER; PRIORITY JOURNAL;

EID: 0034968336     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2001.115023     Document Type: Article

References (30)

1. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency
2. European experience of bone-marrow transplantation for severe combined immunodeficiency
3. PEG-ADA replacement therapy for adenosine deaminase deficiency: An update after 8.5 years
4. PEG-ADA: An alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency
5. Overview of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency
6. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency
7. Effects of deoxyadenosine on ribonucleotide reductase in adenosine deaminase-deficient lymphocytes
8. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: Relevance to the therapeutic use of inhibitors of adenosine deaminase
9. The chondro-osseous dysplasia of adenosine deaminase deficiency with severe combined immunodeficiency
10. Amelioration of neurologic abnormalities after "enzyme replacement" in adenosine deaminase deficiency
11. Sensorineural deafness in siblings with adenosine deaminase deficiency
12. Hepatic dysfunction as a complication of adenosine deaminase deficiency
13. Pathologic findings in adenosine deaminase - Deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro-osseous tissue alterations
14. Adenosine-deaminase -deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death
15. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice
16. The Strengths and Difficulties Questionnaire: A research note
17. The extended version of the Strengths and Difficulties Questionnaire as a guide to child psychiatric caseness and consequent burden
18. Behavioral problems and competencies reported by parents of normal and disturbed children aged four through sixteen
19. Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency
20. Cognitive and academic functioning in survivors of pediatric bone marrow transplantation
21. Cognitive and adaptive behavior 1 and 3 years following bone marrow transplantation
22. Social functioning of children surviving bone marrow transplantation
23. Stress responses after pediatric bone marrow transplantation: Preliminary results of a prospective longitudinal study
24. Adenosine deaminase activity in normal tissues and tissues from a child with severe combined immunodeficiency and adenosine deaminase deficiency
25. 2′-Deoxyadenosine causes cell death in embryonic chicken sympathetic ganglia and brain
26. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients
27. Allogenic bone marrow transplantation in severe Gaucher disease
28. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice: Differential impact on pulmonary and immunologic abnormalities
29. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years
30. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients